IP Library Granted Patent US 8,709,736
Granted Patent B2
US 8,709,736 · App. 12/833,548 · Granted Apr 29, 2014

Biomarker for Barrett's Oesophagus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,709,736
App. No.
12/833,548
Granted
Apr 29, 2014
Kind
B2
Abstract

The present invention relates to the use of TFF3 in the diagnosis and detection of Barrett's esophagus using non-invasive, non-endoscopic methods.

Claims (14)

1. A non-invasive method of screening for Barrett's oesophagus (BE) in a subject comprising:

obtaining a sample of cells, including oesophageal cells, from a subject using a swallowable device comprising an abrasive material configured to be sufficiently abrasive to collect at least some columnar cells in said sample of cells; and

determining the presence of Trefoil factor 3 (TFF3) in said sample of cells, wherein the presence of said TFF3 is indicative of said subject having BE, and wherein the specificity and sensitivity of said method of screening for BE are at least about 80% and about 65% respectively.

2. The method of claim 1 , wherein said cells are a mixed population of cells taken from the cellular surface of the oesophagus.

3. The method of claim 1 , wherein said sample of cells comprise cells from the oesophagus and gastric mucosa cells.

4. The method of claim 1 , wherein said method is non-endoscopic.

5. The method of claim 1 , wherein said subject does not present with BE lesions.

6. The method of claim 1 , wherein said device comprises a capsule sponge.

7. The method of claim 6 wherein the specificity and sensitivity of said method for diagnosis of BE are about 94% and about 78% respectively.

8. The method of claim 1 wherein said TFF3 is detected in an immunoassay using an antibody specific for TFF3.

9. The method of claim 1 wherein the TFF3 is detected using an immunohistochemical detection method.

10. The method of claim 1 further comprising staining the cells with an Alcian Blue stain to confirm diagnosis of BE.

11. The method of claim 1 wherein said abrasive material comprises polyurethane.

12. The method of claim 1 wherein the size and abrasiveness of said material is configured to sample substantially the entire oesophageal lumen of said subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2018
From: MEDICAL RESEARCH COUNCIL
To: UNITED KINGDOM RESEARCH AND INNOVATION
Reel/Frame 046469/0108 →